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Abstract
 
Aims
 
Insulin glargine (IG), with its non-peaking action profile, might be useful in diabetic pregnancy. However, data on
its safety are limited and its use during pregnancy is not recommended. This study focused on the effects of IG on perinatal
outcome, particularly to estimate the rate of congenital anomalies and birthweight.
 
Methods
 
This retrospective study included women with pre-gestational diabetes who used IG before (at least 1 month)
and during pregnancy. For all women we recorded data regarding maternal glycaemic control and pregnancy outcome.
We also compared women treated with IG throughout pregnancy and women who stopped taking IG at an earlier stage.
 
Results
 
From 27 centres, 107 Type 1 diabetic pregnancies were identified. IG was started 10.3 
 
±
 
 6.9 months before
conception and in 57.4% of cases was stopped during the first trimester; 42.6% of women continued using it until the
end of pregnancy. There were six abortions (four spontaneous and two induced) and five newborns (4.9%) with congenital
anomalies. Glycaemic control, birthweight and the prevalence of macrosomia and neonatal morbidity were similar in
women who used IG for the full term compared with those who stopped IG earlier during pregnancy.
 
Conclusions
 
This study, although limited, suggests that IG is safe and effective; the rate of congenital malformations was
within the range expected for diabetic pregnancies treated with more traditional forms of insulin. IG used throughout
pregnancy did not seem to influence birthweight or increase adverse outcomes.
Diabet. Med. 25, 993–996 (2008)
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Introduction
 
Insulin glargine (IG), with its characteristic non-peaking
action profile [1], could be useful in diabetic pregnancies,
where strict glycaemic control and prevention of hypoglycae-
mia are essential to reduce adverse outcomes [2,3]. However,
in view of the lack of controlled data on its safety, the use of
IG is currently not recommended in pregnant women. Another
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potential concern is that the higher affinity of insulin glargine for
the insulin-like growth factor 1 (IGF-1) receptor compared with
other insulin preparations [4] might cause increased fetal growth,
in spite of good glycaemic control. As a consequence, although
IG is frequently prescribed for young patients with diabetes, its
use during pregnancy is still limited and diabetologists have
often discontinued IG during the periconceptional period or at
first consultation during unplanned pregnancies.
To date, studies on IG in pregnancy have involved only a
small number of women with pre-gestational diabetes [5–13]
and more systematic studies are lacking. The Italian Diabetes
Pregnancy Study Group has therefore promoted a national
survey to collect data on the use of IG in women with pre-
gestational diabetes. This study focuses on the effects of IG
on the perinatal outcome, particularly examining the rate of
congenital anomalies and birthweight.
 
Methods
 
This retrospective study included 107 women from 27 Italian
centres with pre-gestational diabetes who used IG before (at
least 1 month) and during pregnancy. Centres were contacted
by scientific diabetology or obstetric societies, during their
national and regional meetings and via their websites. Investi-
gators were asked to record data of all pregnancies in women
with IG-treated pre-gestational diabetes that had ended before
31 December 2006. We collected data from women who had
been treated with IG during their entire pregnancy and women
who had stopped taking IG earlier in pregnancy. The study was
approved by local ethics committees and women gave their
informed consent to the collection of information from their
medical records.
Basal clinical data were gathered from the first visit after
conception: glycated haemoglobin (HbA
 
1c
 
), bodyweight and
insulin therapy were recorded. HbA
 
1c
 
 values at the end of the
pregnancy (1–2 weeks before delivery), frequency of episodes
of severe hypoglycaemia and ketosis were used to assess overall
glycaemic control during pregnancy. Severe hypoglycaemia
was assumed in the event of hypoglycaemic emergencies where
the woman required assistance. Ketosis was considered an
episode of severe hyperglycaemia with an abnormally high
concentration of ketone bodies in urine.
Regarding maternal outcome, gestational hypertension, pre-
eclampsia, eclampsia, time and mode of delivery and maternal
mortality were recorded. Information about abortions was
obtained from hospital records. For neonatal outcome, data were
collected for length and weight at birth, congenital malforma-
tions, shoulder dystocia, hypoglycaemia, fetal distress, jaundice,
stillbirth and early neonatal mortality. Macrosomia was
considered to be a birthweight 
 
>
 
 4000 g; large-for-gestational
age (LGA), if the baby’s birthweight was 
 
>
 
 90th percentile on
the basis of the standard growth and development tables for the
Italian population [14]. Neonatal ponderal index (PI) was
defined as the ratio of weight to length cubed (g/cm
 
3
 
), with a
PI 
 
>
 
 2.85 g/cm
 
3
 
 considered as excessive growth [15]. Admissions
to neonatal intensive care units (NICUs) were also recorded.
Neonatologists made the diagnosis of congenital anomalies
and malformations were classified according to EUROCAT
[16]. Fetal morbidity was classified according to the Obstetrical
Quality indicator [17].
Results from women treated with IG throughout pregnancy
were used to determine the effectiveness of IG on maternal
glycaemic control and birthweight.
All statistical analyses were carried out using the SPSS statistical
package for Windows (SPSS, Chicago, IL, USA). Discrete
variables were compared using a 
 
χ
 
2
 
-test with Yates’ correction
or Fisher’s exact test, as appropriate. Continuous variables
were compared using an unpaired two-sided 
 
t
 
-test.
 
Results
 
We identified 107 Type 1 diabetic pregnancies from the 27
centres. Pregnancy was unplanned in 94% of cases and folic acid
supplementation was not used. All women started IG before
conception (10.3 
 
±
 
 6.9 months) as a basal–bolus regimen. The
first diabetes assessment in pregnancy was at 8.5 
 
±
 
 2.1 weeks
of gestation; the average dose of IG was 19.2 
 
±
 
 7.5 IU/daily
(0.3 
 
±
 
 0.1 IU/kg body weight). At this time, according to the
policy adopted in each single centre, IG was stopped in 57.4%
of cases, while the remaining 42.6% continued using it up to
the end of pregnancy. Patients who stopped IG were switched
to neutral protamine Hagedorn (NPH) insulin (usually in the
morning and at bed-time), with the usual pre-meal insulin.
In all women, glycaemic control improved during pregnancy.
There were no differences in clinical and metabolic parameters
between women who stopped taking IG and those who
continued (Table 1).
Six pregnancies were discontinued because of abortion—
four spontaneous and two induced.
Delivery occurred in 101 pregnancies at 36.7 
 
±
 
 2.1 weeks of
gestation. The rates of pre-term deliveries and Caesarean
section were 29.7 and 79.2% respectively. No maternal death
was reported. All babies were living at birth; one baby, born
preterm at the 29th week of gestation with a weight of 1215 g,
died a few days after delivery; 23.3% of newborns were admitted
to a NICU.
The rates of LGA and excessive growth (PI 
 
>
 
 2.85 g/cm
 
3
 
)
did not differ significantly between women who used IG
throughout the pregnancy and those who stopped it earlier
(Table 1). The rates of macrosomia were also similar in the
two groups (20.9 and 14.8%, respectively). Five newborns
had congenital malformations (4.95%), two cardiovascular,
two genitourinary and one osteoarticular. Mothers of
malformed infants were significantly older (
 
P
 
 
 
<
 
 0.001) than
the others and had had diabetes for longer (
 
P
 
 
 
<
 
 0.04).
 
Discussion
 
This survey collected data on 107 pregnancies of women with
Type 1 diabetes. This is one of the most extensive surveys
reported on this topic in recent years [5–13]. Almost all the
pregnancies were unplanned; in view of the lack of controlled
data on the safety and efficacy of IG, when pregnancy is planned
diabetologists usually change the drug. For the same reason, as
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a policy of the diabetes centres, in our series IG was stopped at
confirmation of pregnancy in a large number of women.
We therefore identified two groups of pregnant women
(Table 1) who were clinically comparable; this was useful as a
basis for assessing the effects of IG on maternal glycaemic
control and on birthweight.
To determine the safety of IG in pregnancy, the study first
focused on congenital malformation, given that IG was used
during embryogenesis in all women. The rate of congenital
anomalies was 4.95%. This figure is within the range (from
3.2 to 9%) expected for diabetic pregnancies treated with
other forms of insulin, as recently reported in several European
countries [18–23]. Moreover, in a previous multicentre survey
of 504 Italian women with pre-gestational Type 1 diabetes
(none taking IG either before or during pregnancy), we found
a similar rate of congenital malformations of 5.9% [24]. It is
worth noting that 19 out of 27 centres were involved in both
surveys and that the two cohorts of pregnant diabetic women
had similar clinical and metabolic characteristics. Thus, the
present results suggest that IG has no negative effects on
embryo–fetal development.
Another issue is the potential effect on fetal growth. One
concern is that the higher affinity of IG for IGF-1 receptor
compared with other insulin preparations [4] could potentially
cause fetal macrosomia. However, in our series, the use of
IG throughout pregnancy was not associated with higher
birthweight or any change in neonatal outcome. In addition,
the prevalence of macrosomia and/or LGA infants was no
different from women who used NPH insulin in pregnancy.
This result might possibly be because of comparable metabolic
parameters (HbA
 
1c
 
 at the end of pregnancy, episodes of
hypoglycaemia and ketosis) in the two groups, factors
which are the main determinants of birthweight in diabetic
pregnancies [25]. Thus, as recently reported in other studies
[11,12], the absence of higher rates of macrosomic and LGA
babies in women treated with IG does seem to exclude any
increase in the risk of fetal overgrowth as a result of this type
of therapy.
Although we are aware of the limited size of our cohort and
the need for larger randomized trials in order to strengthen the
findings, this survey, which at present is one of the largest
reporting pregnancy outcomes in women treated with IG,
suggests that IG is safe and effective. IG use did not increase
the rate of congenital malformations in women with pre-
gestational diabetes and did not seem to influence birthweight.
In conclusion, IG in pregnancy seems to give much the same
maternal–neonatal outcomes as older insulins.
 
Participating investigators
 
The members of the Italian Diabetes and Pregnancy Study
Group—Italian Society of Diabetology include: Graziano Di
Table 1 Maternal and fetal outcome according to type of insulin treatment
Group A (n = 43) Group B (n = 58) P
Mothers
Age (years) 30.6 ± 3.5 30.4 ± 4.1 0.79
Diabetes duration (years) 16.8 ± 8.7 15.9 ± 6.5 0.55
Pre-pregnancy BMI (kg/m2) 23.2 ± 4.9 24.2 ± 3.4 0.325
Weight gain (kg) 14.1 ± 4.1 13.3 ± 4.4 0.35
HbA1c (%)
—first measurement in pregnancy 7.7 ± 1.32 7.6 ± 1.09 0.688
—at the end of pregnancy 6.5 ± 0.79 6.5 ± 0.91 0.97
Patients with hypoglycaemic episodes (%) 9.3 12.1 1.00
Patients with episodes of ketosis (%) 11.6 6.9 0.56
Gestational hypertension (%) 2.3 3.4 0.32
Pre-eclampsia (%) 2.3 8.6 0.8
Time of delivery (weeks) 37.2 ± 1.5 36.4 ± 2.4 0.045
Caesarean section (%) 79.1 79.3 0.89
Newborns
Large for gestational age (%)  44.1 41.3 0.85
Ponderal index (kg/cm3) 2.8 ± 0.4 2.8 ± 0.3 0.92
Ponderal index > 2.85 (%) 45.0 46.9 1
Congenital malformations (%) 4.7 5.2 1
NICU admissions (%) 25.7 21.5 0.4
Neonatal hypoglycaemia (%) 14.6 17.2 0.72
Hyperbilirubinaemia (%) 19.5 22.2 0.62
Group A: patients with insulin glargine throughout pregnancy.
Group B: patients who stopped insulin glargine in pregnancy and started using intermediate human insulin. 
BMI, body mass index; HbA1c, glycated haemoglobin; NICU, neonatal intensive care unit.
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